Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comment light on for FDA and tobacco

This article was originally published in The Tan Sheet

Executive Summary

FDA solicits public comment on topics concerning its authority over tobacco products established by recently enacted Family Smoking Prevention and Tobacco Control Act, including smoking cessation, prevention and federal, state and local government collaboration. After the Center for Tobacco Products required by the law is established, FDA will seek comment on more specific issues on reducing the incidence and prevalence of tobacco use and protecting public health, according to a July 1 Federal Register notice (1"The Tan Sheet" June 15, 2008). Also included among the comment topics are new product submission and approval; ingredient disclosure; tobacco use by specific groups; tobacco addiction; data collection; products with reduced harm/risk claims; enforcement; research and testing; advertising and marketing; label statements and warnings; standards - including flavors and ingredients; sale and distribution; and manufacturing restrictions and facilities controls. The deadline for comments is Oct. 28

You may also be interested in...



Tight 90-Day Countdown To Create Tobacco Center Poses Challenge To FDA

FDA has its work cut out for it to establish a Center for Tobacco Products within 90 days, once President Obama adds his promised signature to the bill giving the agency regulatory authority over tobacco

Canada Boosts Postmarket Device Safety With New Reporting Rules

Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.

Valneva Starts COVID-19 Vaccine Production In Scotland

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel